This patent covers the use of NGF for storing corneal samples, but also for use as a topical solution for the treatment of diseases associated with corneal dysfunction.
This patent claims that expression of the anti-apoptotic gene bcl-2 can be used as a marker for stem cells of the muscle. The problem is that bcl-2 is an intracellular molecule, therefore it is difficult to selectively purify based on its expression. If a colourogenic substrate for bcl-2 can be discovered or already exists, this would greatly increase the value of the current patent.
This patent provides devices that can quantify hematopoietic stem cell numbers from a pool of cells through non-immunological means.
This patent appears to cover a new method of detecting hematopoietic stem cells, without needing to use stem cell-specific markers. The patent seems to use some light and physical properties of the cells to distinguish between stem cells and non-stem cells. The patent has one issued claim which is: "A method for detecting or counting or both detecting and counting hematopoietic...
This patent covers peptides that inhibit hematopoietic stem cell proliferation, thereby allowing protection of these cells from chemotherapy or radiotherapy. This patent may conceptually be applicable to selectively inhibiting healthy stem cells while allowing leukemic stem cells to proliferate so that chemotherapy or radiotherapy may selectively kill the proliferating leukemic cells.
This patent discloses lectins and portions of the lectins that are capable of protecting various types of stem cells from death or inactivation.
This patent teaches that mesenchymal stem cells in the bone marrow are sometimes found in attachment to megakaryocytes. The patent teaches that it is possible to extracted megakaryocytes from the bone marrow, using antibodies such as anti-CD41, and then from the megakaryocytes to de-attach the mesenchymal stem cells.
This patent covers an antibody that binds CD34 cells called MG-1. This is a useful patent for people trying to circumvent Baxter's CD34 patent or Miltenyi's CD133.
This is a patent for a unique stem cell marker that is recognized by the antibody MG-1. There are numerous stem cell markers in existence which are used for isolation of stem cell subtypes. The value of new stem cell markers is relatively high since the field is very populated. A patent such as the present one, if MG-1 has not been commercialized, can be used to position a new biotech...
This patent covers an antigen that is found on some types of hematopoietic stem cells. This antigen can be used for purification of hematopoietic stem cells by magnetic or flow cytometric means.